EU Report Announces Drugmaker Probes Over Deals

By Melissa Lipman

Law360, New York (July 08, 2009, 12:00 AM ET) -- Citing concerns over settlements between generic- and brand-name drug companies that may slow the arrival of cheaper medicines on the market, the European Commission announced formal investigations of a French drugmaker and several generics makers Wednesday and warned that more inquiries would likely follow.

But in releasing its final report on competition in the pharmaceutical sector, the commission conceded that the delay in generic drugs entering the market could stem from "shortcomings in the regulatory framework" in addition to the behavior of the drugmakers themselves....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles